Boehringer Ingelheim

As COVID-19 revenues ebb and flow—but mostly ebb—Pfizer is eyeing the cost-cutting shears. | Paxlovid generated just $143 million in worldwide sales for the second quarter, while mRNA vaccine Comirnaty brought home $1.4 billion. Against that backdrop, Pfizer reported total second quarter revenues of $12.7 billion, down a whopping 53% operationally from the same period…

Gearing up for the launch of diabetes and heart failure drug Jardiance in chronic kidney disease, Boehringer Ingelheim has already started 2023 by posting strong pharma sales growth. | Boehringer reported an 11.3% jump in pharma sales during the first half of the year, largely thanks to Eli Lilly-partnered Jardiance. Now, the company is kicking off a chronic…

Eight months after Briumvi’s initial green light in the U.S., TG Therapeutics is preparing to debut its multiple sclerosis antibody on the world stage. | European specialty pharmaceutical company Neuraxpharm will throw TG an upfront payment of $140 million—plus an additional $12.5 million upon Briumvi’s first EU launch—to chip in on commercialization of TG’s CD20-targeting…

NANTES, France, August 01, 2023--(BUSINESS WIRE)--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230731253198/en/ OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company has received €200,000 grant innovation funding from the French Government and Region Pays de la Loire as part of the "France 2030 investment plan" operated…

ReportLinker Cancer patients frequently receive radiotherapy as treatment, therefore, Radiotherapy segment acquired $5,335.2 million revenue in the market in 2022. Furthermore, it uses radiation to kill malignant cells or stop them from proliferating. New York, July 31, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Quantum Computing in Healthcare Market Size,…

With a European approval for chronic kidney disease nod in hand, Boeringer Ingelheim and Eli Lilly's Jardiance is looking to catch up to AstraZeneca's Farxiga in this use and continue growing its r | After recent label expansions in the U.S. and Europe paid off with a sizable sales increase for Jardiance, the drug has added a third use…

After triumphing over Novartis’ Cosentyx in a 2020 psoriasis study, Skyrizi has dished out another serving of competitor-busting data. | AbbVie's Skyrizi has dished out another serving of competitor-busting data, this time going head-to-head against Amgen’s Otezla.

American Indian and Alaska Native children experience high rates of RSV-related hospitalizations | Image Credit: © jarun011 - © jarun011 - stock.adobe.com. Findings from a study recently published in Pediatrics show American Indian and Alaska Native (AI/AN) children are dealing with high rates of respiratory syncytial virus (RSV)-associated acute respiratory infection (ARI) hospitalizations. RSV-associated rates…

Patient groups focused on lung diseases have observed an overall improvement in the pharmaceutical industry's reputation in 2022 compared to the previous year. | Patient groups focused on lung diseases have observed an overall improvement in the pharmaceutical industry's reputation in 2022 compared to the previous year. Nevertheless, they continue to identify two major concerns…

Published on: May 17, 2023 In this interview, Arun Thachi, Director, Head of IT Marketing and Sales, Boehringer Ingelheim, discusses the AI journey in pharma. Arun Thachi, Director, Head of IT Marketing and Sales, Boehringer Ingelheim, explains conversational AI and how it can be best-used in pharma to inform and engage.

Independent shops scoop up 40% of briefs.

The collaboration aims to advance novel treatments for geographic atrophy patients using artificial intelligence. Credit: salvatore ventura on Unsplash. …